(Q38081239)

28 August 2017

title

Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways (English)

1 reference

28 August 2017

Aaron Provenzano

1

1 reference

28 August 2017

Sobha Kurian

series ordinal

2

1 reference

28 August 2017

Jame Abraham

series ordinal

3

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Expert Review of Anticancer Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

143-147

1 reference

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Regulation of mammalian autophagy in physiology and pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

The roles of therapy-induced autophagy and necrosis in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

PI3K pathway inhibitors approach junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.173

21 January 2018

Identifiers

DOI

10.1586/ERA.12.173

1 reference

28 August 2017

1 reference